Literature DB >> 22806898

Using the time-to-event continual reassessment method in the presence of partial orders.

Nolan A Wages1, Mark R Conaway, John O'Quigley.   

Abstract

The time-to-event continual reassessment method (TITE-CRM) was proposed to handle the problem of long trial duration in Phase 1 trials as a result of late-onset toxicities. Here, we implement the TITE-CRM in dose-finding trials of combinations of agents. When studying multiple agents, monotonicity of the dose-toxicity curve is not clearly defined. Therefore, the toxicity probabilities follow a partial order, meaning that there are pairs of treatments for which the ordering of the toxicity probabilities is not known at the start of the trial. A CRM design for partially ordered trials (PO-CRM) was recently proposed. Simulation studies show that extending the TITE-CRM to the partial order setting produces results similar to those of the PO-CRM in terms of maximum tolerated dose recommendation yet reduces the duration of the trial.
Copyright © 2012 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2012        PMID: 22806898      PMCID: PMC3521068          DOI: 10.1002/sim.5491

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  7 in total

1.  Continual reassessment method: a likelihood approach.

Authors:  J O'Quigley; L Z Shen
Journal:  Biometrics       Date:  1996-06       Impact factor: 2.571

2.  Continual reassessment method: a practical design for phase 1 clinical trials in cancer.

Authors:  J O'Quigley; M Pepe; L Fisher
Journal:  Biometrics       Date:  1990-03       Impact factor: 2.571

3.  Dose-finding design for multi-drug combinations.

Authors:  Nolan A Wages; Mark R Conaway; John O'Quigley
Journal:  Clin Trials       Date:  2011-06-07       Impact factor: 2.486

4.  Continual reassessment method for partial ordering.

Authors:  Nolan A Wages; Mark R Conaway; John O'Quigley
Journal:  Biometrics       Date:  2011-03-01       Impact factor: 2.571

5.  Sequential designs for phase I clinical trials with late-onset toxicities.

Authors:  Y K Cheung; R Chappell
Journal:  Biometrics       Date:  2000-12       Impact factor: 2.571

6.  Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNA-alkyltransferase: phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors.

Authors:  Malcolm Ranson; Mark R Middleton; John Bridgewater; Siow Ming Lee; Martin Dawson; Debra Jowle; Gavin Halbert; Sue Waller; Helen McGrath; Lindsey Gumbrell; R Stanley McElhinney; Dorothy Donnelly; T Brian H McMurry; Geoffrey P Margison
Journal:  Clin Cancer Res       Date:  2006-03-01       Impact factor: 12.531

7.  Model calibration in the continual reassessment method.

Authors:  Shing M Lee
Journal:  Clin Trials       Date:  2009-06       Impact factor: 2.486

  7 in total
  6 in total

1.  A Bayesian model-free approach to combination therapy phase I trials using censored time-to-toxicity data.

Authors:  Graham M Wheeler; Michael J Sweeting; Adrian P Mander
Journal:  J R Stat Soc Ser C Appl Stat       Date:  2018-11-22       Impact factor: 1.864

Review 2.  Practical designs for Phase I combination studies in oncology.

Authors:  Nolan A Wages; Anastasia Ivanova; Olga Marchenko
Journal:  J Biopharm Stat       Date:  2016       Impact factor: 1.051

3.  pocrm: an R-package for phase I trials of combinations of agents.

Authors:  Nolan A Wages; Nikole Varhegyi
Journal:  Comput Methods Programs Biomed       Date:  2013-07-18       Impact factor: 5.428

4.  Specifications of a continual reassessment method design for phase I trials of combined drugs.

Authors:  Nolan A Wages; Mark R Conaway
Journal:  Pharm Stat       Date:  2013-06-03       Impact factor: 1.894

5.  BAYESIAN DATA AUGMENTATION DOSE FINDING WITH CONTINUAL REASSESSMENT METHOD AND DELAYED TOXICITY.

Authors:  Suyu Liu; Guosheng Yin; Ying Yuan
Journal:  Ann Appl Stat       Date:  2013-12-01       Impact factor: 2.083

6.  Practicalities in running early-phase trials using the time-to-event continual reassessment method (TiTE-CRM) for interventions with long toxicity periods using two radiotherapy oncology trials as examples.

Authors:  Erik van Werkhoven; Samantha Hinsley; Eleni Frangou; Jane Holmes; Rosemarie de Haan; Maria Hawkins; Sarah Brown; Sharon B Love
Journal:  BMC Med Res Methodol       Date:  2020-06-22       Impact factor: 4.615

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.